'Protein printing' AbSci secures $125M crossover as it expands synthetic biology ambitions

Max Gelman

Senior Editor

Two months after acquiring an AI engine it claims can potentially speed up drug development by “unprecedented” levels,” AbSci has secured a hefty crossover round …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

'Protein printing' AbSci secures $125M crossover as it expands synthetic biology ambitions

Max Gelman

Senior Editor

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

BridgeBio shares promising results in trial of Canavan disease gene therapy

CRISPR therapy reduces swelling attacks by 81% in Intellia follow-up study

Facing lost rebates, MGM Resorts to stop covering GLP-1 weight loss shots

Exclusive: University of Toronto spinout raises $53.5M to create new obesity drugs with AI

Icon's quarterly earnings hit by biotech and pharma pullback

IDEAYA Biosciences: Targeting unmet market needs with precision oncology

'Pro­tein print­ing' Ab­Sci se­cures $125M crossover as it ex­pands syn­thet­ic bi­ol­o­gy am­bi­tions

Senior Editor

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

'Protein printing' AbSci secures $125M crossover as it expands synthetic biology ambitions